After eight treatments, TIMP1, MMP7, and TSP2 were significantly lower (P < 0.05) in the responding (gemcitabine + NAB‐P group) compared to the non‐responding tumors (gemcitabine group), thus suggesting they were potential markers for monitoring tumor response and treatment efficacy. The gene discussed is TIMP1; the disease is neoplasm.